Digital endpoints offer enormous promise to transform medical product development and the reach of new therapies to all patients, including individuals typically underrepresented in clinical research.
This summer, DiMe is collaborating with colleagues at the Clinical Trials Transformation Initiative (CTTI), and Transcelerate to highlight the best resources available to sponsors, digital product manufacturers, and researchers committed to harnessing the power of digital clinical trials to advance the safe, effective, ethical, and equitable use of digital technologies to improve lives through new approaches to medical product development. Register now for the first session, led by DiMe CEO Jen Goldsack and moderated by Rachel Chasse, in the three-part series from CTTI, DiMe, and TransCelerate.
